DUBLIN--(BUSINESS WIRE)--The "Microbiome Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, till 2035: Distribution by Type of Product Manufactured, Type of Formulation, Type of Primary Packaging Used, Scale of Operation, Company Size, Key Geographical Regions and Leading Developers" report has been added to ResearchAndMarkets.com's offering.

The global microbiome manufacturing market size is estimated to grow from USD 27 billion in 2023 to USD 187 billion by 2035, representing a CAGR of 17% during the forecast period 2023-2035.

The key objective of this market report is to provide a detailed market forecast analysis in order to estimate the existing microbiome manufacturing market size and future opportunity for microbiome manufacturers over the next decade. Based on several parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period 2023-2035.

The human body is known to harbor numerous communities of microbes, including both beneficial and harmful species, which are collectively referred to as microbiota. Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome. Given the role of the microbiota in both disease development and pathogenesis, the concept of microbiome-based therapeutics has, over time, piqued the interest of the medical science community.

In fact, the last two decades have witnessed several developments in the field of microbiome therapy research and their therapeutic applications. Live biotherapeutic products (LBP), a class of microbiome therapy, involve the use of live microorganisms, such as bacteria, viruses, or fungi, to prevent or treat various disease conditions. LBPs are specifically designed for therapeutic purposes and are regulated as medicinal products or biologics in many countries.

These therapeutic modalities consist of well-characterized specific strains of microorganisms that are extensively researched for their intended medical applications, followed by rigorous testing and clinical trials to demonstrate safety and efficacy for treating or preventing specific medical condition. Further, the microbiome-based therapeutic approach has the potential to profile the microbiome composition of the patient using gene sequencing; this will lead to the development of tailored treatment options.

Microbiome Manufacturing Market Key Market Insights

The report features an extensive study of the current market landscape, market size and future opportunities for the microbiome manufacturing companies, including those involved in live biotherapeutic manufacturing, during the given forecast period. Further, this microbiome manufacturing market analysis highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the microbiome manufacturing market report are briefly discussed below.

Competitive Landscape of Microbiome Manufacturing Companies

The microbiome manufacturing market features a mix of large, mid-sized and small in-house players and contract manufacturing organizations that are engaged in the production of microbiome therapy across different scales of operations, such as preclinical, clinical, and commercial. Currently, 50% of the microbiome therapy contract manufacturers offer services for both API and FDF manufacturing; notable examples (in alphabetical order) include Arranta Bio, BacThera, Biose, Capsugel and Cerbios-Pharma. In addition, majority of the microbiome companies offer probiotic manufacturing services on a contract basis.

Clinical Trials Analysis: Close to 170 Trials are Evaluating Microbiome Therapeutics to Treat Various Infectious Diseases and Oncological Disorders

Over the years, microbiome companies involved in the manufacturing of microbiome therapeutics have made significant efforts to conduct clinical trials for evaluating the efficacy of microbiome therapies targeting various disorders, including infectious diseases, neurological disorders and oncological disorders.

Close to 170 clinical trials have been conducted across different geographical regions to evaluate various microbiome therapies, of which, majority (70%) were registered in North America. Further, the maximum number of patients (10,138) were observed to be enrolled in clinical trials conducted in North America, which account for 52% of the overall enrollment. It is worth mentioning that AOBiome is conducting the maximum number of trials in this industry for different dermatological, respiratory and CNS disorders. In addition, VE303 (developed by Vedanta Biosciences) for the treatment of recurrent Clostridium difficile infection has demonstrated positive results in the Phase II clinical trials.

Market Trends Analysis: Partnerships and Collaborations have Fueled Microbiome Manufacturing Market Growth

Several stakeholders have been forging alliances with other industry / non-industry players in the microbiome therapeutics contract manufacturing industry. It is worth highlighting that since 2018, over 50 strategic partnerships have been established in this domain, of which the majority are focused on research, product development, and technology utilization.

Microbiome Contract Manufacturing Companies' Capacity Utilization Rate is Expected to Increase Significantly in the Coming Years

Around 43% of the global microbiome contract manufacturing capacity is installed in facilities owned by small contract manufacturing companies. Further, majority share (57%) of the overall microbiome manufacturing capacity is installed in facilities located in Europe; within Europe, more than 35% of this capacity is installed in facilities owned by players based in Austria.

Microbiome Manufacturing Market Size: Europe to Hold the Largest Market Share

The microbiome manufacturing market is estimated to be worth USD 27 million in 2023. Driven by the growing pipeline of microbiome-based products, the microbiome manufacturing market is anticipated to grow at a CAGR of 17% during the forecast period. Specifically, in terms of type of product manufactured, majority of the market share is anticipated to be captured by APIs by 2035. Further, the liquid dosage form continues to hold the largest share (50%) in the contract manufacturing industry.

Leading Contract Manufacturing Companies Engaged in Microbiome Manufacturing Market

Examples of key microbiome contract manufacturing companies (which have also been profiled in this report) offering manufacturing services include (in alphabetical order) Biose, BJP Laboratories, Capsugel, Cerbios-Pharma, Chr. Hansen, Inpac Probiotics, NIZO, WACKER and Winclove. In addition, MaaT Pharma is in the process of expanding its cGMP manufacturing capacity through the addition of a new plant in France that will exclusively focus on microbiome therapeutics manufacturing; the plant is set to be operational before the end of 2023. This market report includes an easily searchable excel database of all the microbiome contract manufacturing companies and their manufacturing facility, worldwide.

Key Attributes:

COMPANY PROFILES

Leading Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America

• Capsugel (Acquired by Lonza)
  • Company Overview
  • Service Portfolio
  • Facilities Dedicated to Microbiome Manufacturing
  • Recent Developments and Future Outlook

Other Prominent Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America

• Arranta Bio
• FUJIFILM Diosynth Biotechnologies
• List Biological Laboratories
• ProbioFerm

Leading Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe

• Biose Industrie
• Cerbios-Pharma
• Chr. Hansen
• Inpac Probiotics
• NIZO
• WACKER
• Winclove Probiotics

Other Prominent Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe

• BacThera
• Evologic Technologies
• Probiotical
• QUAY Pharma

Leading Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific

• BJP Laboratories

Other Prominent Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific

• Aumgene Biosciences
• AcuraBio
• Meteoric Biopharmaceuticals
• Probiotics Australia
• Unique Biotech

Scope of the Report

• Base Year: 2022
• Forecast Period: 2023-2035
• Market Size 2023: $27 Million
• CAGR: 17%
• Customization Scope: 15% Customization Available
• PowerPoint Presentation: (Complimentary)
• Type of Product Manufactured
  • API
  • FDF
• Type of Formulation
  • Solid
  • Liquid
  • Others
• Type of Primary Packaging Used
  • Blister Packs
  • Glass / Plastic Bottles
  • Pouches / Sachets
  • Vials
• Scale of Operation
  • Clinical
  • Commercial
• Company Size
  • Small
  • Mid-sized
  • Large and Very Large
• Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Leading Developers
  • Infant Bacterial Therapeutics
  • MaaT Pharma
  • Microbiomik Healthcare
  • OxThera
  • Rebiotix
  • Seres Therapeutics
• Key Companies Profiled
  • Biose
  • BJP Laboratories
  • Capsugel
  • Chr. Hansen
  • Inpac Probiotics
  • NIZO
  • WACKER
  • Winclove
  • (Full list of more than 60 companies captured is available in the report)
• Excel Data Packs: (Complimentary)
  • Market Landscape Analysis
  • Company Competitiveness Analysis
  • Likely Partner Analysis
  • Big Pharma Initiatives
  • Recent Developments and Initiatives
  • Clinical Trial Analysis
  • Capacity Analysis
  • Demand Analysis
  • Market Forecast and Opportunity Analysis

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry:

• Founder and Executive Chairman, Small Company, US
• Managing Director and Scientific Head, Large Company, India
• Managing Director and Chief Executive Officer, Mid-sized Company, India
• Co-Founder and Chief Executive Officer, Small Company, Belgium
• Founder and Chief Executive Officer, Small Company, US
• Chief Business Officer, Mid-sized Company, Israel
• Chief Operating Officer, Mid-sized Company, US
• Vice President, Business Development, Small Company, US
• Vice President, Commercial Operations, Mid-sized Company, US
• Vice President, Business Development, Mid-sized Company, US
• Vice President, Sales and Business Development, Small Company, US
• Head of Business Development, Mid-sized Company, Australia
• Business Development Manager, Large Company, Germany

For more information about this report visit https://www.researchandmarkets.com/r/r6ef9m

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900